-
Notifications
You must be signed in to change notification settings - Fork 14
investigate OpenFDA as a data source for compound relationships #131
Comments
Explanation below is paraphrased from an email from Tyler. It seems that all the information is there to get official FDA info on drugs-target relationships. Would be great to figure out whether this can be set up as a BTE-compatible SmartAPI... There are several steps involved in going to UNIPROT IDs, but it’s usually possible. In the case below, the link to targets as part of the relationships is here:
https://api.fda.gov/other/substance.json?search=uuid:%2200b709bc-7f21-4daf-91bc-3e17f9d26ab7%22 That’s a link to the full record associated (I used the refuuid as the uuid search, but could have used the UNII instead). If you look inside that record’s “codes” section, you see this:
A few things to note here:
|
The OpenFDA API may be a useful source of relationships between compounds and other entities (including protein targets). (EDIT 2020-10-28: separated out the issue of compound properties from OpenFDA into another ticket: biothings/biothings_explorer#132.)
The OpenFDA API is described at https://open.fda.gov/apis/. The primary key is UNII. For example, drug report for afatinib (UNII:
41UD74L59M
) is at https://api.fda.gov/other/substance.json?search=unii:%2241UD74L59M%22 .The Relationships section has a variety of relationships to other entities. Among these are
TARGET->INHIBITOR
relationships to proteins that the drug targets (including specific protein variants). (Yes, we have drug targets through other resources, but consulting an FDA API seems to be quite valuable from a provenance standpoint.) The current challenge is that the protein targets are also indexed by UNII IDs, and I'm not aware of any resource to translate those to other protein identifiers (e.g., UniProt).In some cases, there is additional quantitative information on those relationships. For example, from the record for Acalabrutinib https://api.fda.gov/other/substance.json?search=uuid:%229d4c7efc-e2a1-4b9c-8d57-559ef5dd30b2%22, we see that the
Acalabrutinib
inhibits
BTK
edge also has qualifiers that the IC50 is 5nM and that it is an irreversible inhibitor:Referencing is very good, with statement-level references to primary literature, databases, documents from FDA/WHO, etc.
(ref: email from Tyler Peryea to me, 2020-10-26)
The text was updated successfully, but these errors were encountered: